Royal DSM NV (DSM)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Royal DSM NV (DSM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010863
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Royal DSM NV (DSM) is a life sciences and materials sciences company, which focuses on health, nutrition and materials sectors. The company offers a wide range of products such as anti-invectives, polyesters, vitamins and other ingredients, performance materials to diverse end markets. It provides products and services to animal and human health and nutrition, personal care, pharmaceuticals, dietary supplements, automotive, medical materials, food and beverages, packaging, electrical and electronics, coatings and paints, alternative energy, housing, life protection and bio-based materials markets. It has operations in Europe, Americas, Africa, the Middle East and Asia Pacific. DSM is headquartered at Heerlen, the Netherlands.

Royal DSM NV (DSM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Royal DSM NV, Medical Devices Deals, 2011 to YTD 2017 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Royal DSM NV, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Partnerships 16
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 17
Royal DSM Forms Joint Venture With JLL Partners 18
DSM Enters Into Co-Development Agreement With AdeTherapeutics 20
Royal DSM Forms Joint Venture With Sinochem Group 21
Provexis Enters Into Co-Development Agreement With DSM Nutritional Products 23
Equity Offering 24
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 24
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Debt Offering 28
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
Acquisition 31
i-Health to Acquire UP4 Probiotics from UAS Labs 31
Royal DSM To Acquire Aland Nutraceutical 32
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 33
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 35
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 37
Viocare Acquires DSM Personalized Nutrition From Royal DSM 39
Royal DSM Acquires Martek Biosciences 40
Royal DSM NV – Key Competitors 42
Royal DSM NV – Key Employees 43
Royal DSM NV – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 47
Recent Developments 49
Strategy And Business Planning 49
Apr 03, 2017: Royal DSM Opens New Biotechnology Center in Delft, the Netherlands 49
Financial Announcements 50
Nov 02, 2017: DSM Reports Results First Nine Months 2017 50
May 02, 2017: DSM Q1 2017 Results 51
Feb 15, 2017: DSM reports 2016 results 52
Feb 14, 2017: DSM new presentation of accounts as from Q4 2016 56
Aug 02, 2016: DSM Q2 2016 results 57
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Royal DSM NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Royal DSM NV, Deals By Therapy Area, 2011 to YTD 2017 9
Royal DSM NV, Medical Devices Deals, 2011 to YTD 2017 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 17
Royal DSM Forms Joint Venture With JLL Partners 18
DSM Enters Into Co-Development Agreement With AdeTherapeutics 20
Royal DSM Forms Joint Venture With Sinochem Group 21
Provexis Enters Into Co-Development Agreement With DSM Nutritional Products 23
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 24
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
i-Health to Acquire UP4 Probiotics from UAS Labs 31
Royal DSM To Acquire Aland Nutraceutical 32
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 33
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 35
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 37
Viocare Acquires DSM Personalized Nutrition From Royal DSM 39
Royal DSM Acquires Martek Biosciences 40
Royal DSM NV, Key Competitors 42
Royal DSM NV, Key Employees 43
Royal DSM NV, Other Locations 44
Royal DSM NV, Subsidiaries 44
Royal DSM NV, Joint Venture 47

★海外企業調査レポート[Royal DSM NV (DSM)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NovAliX SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary NovAliX SAS (NovAliX) is a contract research organization that offers outsourcing and insourcing research services for drug discovery. The organization provides chemical biology services such as chemistry, biophysics, drug discovery and protein purification services. Its biophysics services …
  • Bristol-Myers Squibb Co (BMY):企業の財務・戦略的SWOT分析
    Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Anika Therapeutics Inc (ANIK)-製薬・医療分野:企業M&A・提携分析
    Summary Anika Therapeutics Inc (Anika) is a medical technology company which develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products i …
  • Spicers Limited (SRS):企業の財務・戦略的SWOT分析
    Spicers Limited (SRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Jubilant Biosys Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Jubilant Biosys Ltd (Jubilant Biosys), a subsidiary of Jubilant Life Sciences Ltd, is a provider of drug discovery and development solutions. The company offers functional discovery services such as toxicology models, computational chemistry, medicinal chemistry, structural biology, drug met …
  • Infosys Limited:戦略・SWOT・企業財務分析
    Infosys Limited - Strategy, SWOT and Corporate Finance Report Summary Infosys Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Aushon BioSystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that provides biomarker measurement and analysis products. The company offers biomarker therapeutic areas in microarray printing technology. It provides products such as ciraplex assay, cirascan imaging and cirasoft analysis and cir …
  • Mapletree Logistics Trust Management Ltd:企業の戦略・SWOT・財務情報
    Mapletree Logistics Trust Management Ltd - Strategy, SWOT and Corporate Finance Report Summary Mapletree Logistics Trust Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • BioIQ Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioIQ Inc (BioIQ) is a healthcare technology company that offers health and wellness programs. The company’s dimensions screening platforms comprise lab testing, physician results, at-home testing, and flu vaccinations, among others. It offers axis integration platforms such as Bioiq ecosyst …
  • Beltrami Electric Cooperative, Inc.:発電所・企業SWOT分析
    Beltrami Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Ballard Power Systems Inc. (BLDP)-エネルギー分野:企業M&A・提携分析
    Summary Ballard Power Systems Inc. (Ballard Power) is a renewable energy company. It designs, develops, manufactures, sells, and services proton exchange membrane (PEM) fuel cell products for power product markets, portable power, and material handling and backup power. The company’s product lines i …
  • Noven Pharmaceuticals, Inc.:企業の戦略・SWOT・財務情報
    Noven Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Noven Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Pakistan State Oil Co Ltd (PSO):企業の財務・戦略的SWOT分析
    Pakistan State Oil Co Ltd (PSO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • EQT Corp (EQT):石油・ガス:M&Aディール及び事業提携情報
    Summary EQT Corp (EQT) is an integrated oil and gas company. It operates production fields in Marcellus, Upper Devonian, Ohio Utica and other plays in Appalachian Basin. The company produces and markets natural gas, natural gas liquids (NGL), ethane and crude oil. EQT provides gathering, transmissio …
  • Unipetrol, a.s. (UNIPE):石油・ガス:M&Aディール及び事業提携情報
    Summary Unipetrol AS (Unipetrol), a subsidiary of Polski Koncern Naftowy Orlen SA, is refinery and petrochemical company. The company produces and sells petroleum products, petrochemicals, plastics and specialty chemicals. Unipetrol owns and operates transport services, filling stations and carries …
  • Venus Remedies Ltd (VENUSREM):製薬・医療:M&Aディール及び事業提携情報
    Summary Venus Remedies Ltd (Venus) is a pharmaceutical company that develops, manufactures and commercializes research, herbal and generic products. The company’s manufactures products for analgesic and antipyretic, antibiotic, anticoagulant, disinfectant and antiseptic, iron supplement, neurology, …
  • Dynasty Fine Wine Group Limited:企業の戦略・SWOT・財務分析
    Dynasty Fine Wine Group Limited - Strategy, SWOT and Corporate Finance Report Summary Dynasty Fine Wine Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Empire Co Ltd:企業の戦略・SWOT・財務情報
    Empire Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Empire Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Safe Orthopaedics SA (SAFOR)-医療機器分野:企業M&A・提携分析
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical equipment company that manufactures and markets minimally invasive devices for spinal surgery. The company’s product portfolio includes implants and surgical instruments. It offers modular cervical cages, percutaneous auto-correction screws …
  • Oncopeptides AB (ONCO):製薬・医療:M&Aディール及び事業提携情報
    Summary Oncopeptides AB (Oncopeptides) is a clinical development pharmaceutical company that offers development of oncology therapies to treat multiple myeloma. The company’s lead product candidate Ygalo (melflufen) is a peptidase potentiated cytotoxic drug and a potent anti-angiogenetic compound, a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆